| Year |
Citation |
Score |
| 2022 |
Espinosa-Cotton M, Cheung NV. Bispecific antibodies for the treatment of neuroblastoma. Pharmacology & Therapeutics. 237: 108241. PMID 35830901 DOI: 10.1016/j.pharmthera.2022.108241 |
0.307 |
|
| 2021 |
Espinosa-Cotton M, Cheung NV. Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor. Frontiers in Oncology. 11: 772862. PMID 34869013 DOI: 10.3389/fonc.2021.772862 |
0.332 |
|
| 2020 |
Luo LY, Kramer K, Cheung NV, Kushner BH, Modak S, Basu EM, Roberts SS, Wolden SL. Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma. Pediatric Blood & Cancer. e28364. PMID 32608559 DOI: 10.1002/Pbc.28364 |
0.333 |
|
| 2020 |
Park JA, Cheung NV. Targets and Antibody Formats for Immunotherapy of Neuroblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901410. PMID 32167865 DOI: 10.1200/Jco.19.01410 |
0.426 |
|
| 2020 |
Santich BH, Park JA, Tran H, Guo HF, Huse M, Cheung NV. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Science Translational Medicine. 12. PMID 32161106 DOI: 10.1126/Scitranslmed.Aax1315 |
0.356 |
|
| 2020 |
Casey DL, Cheung NV. Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies. Cancer Immunology Research. 8: 161-166. PMID 32015013 DOI: 10.1158/2326-6066.Cir-19-0692 |
0.405 |
|
| 2019 |
Wang L, Cheung NV, Hoseini SS, Xu H, Ponomarev V. Silencing Fc domains in T Cell-Engaging Bispecific Antibodies Improves T-Cell Trafficking and Antitumor Potency. Cancer Immunology Research. PMID 31615814 DOI: 10.1158/2326-6066.Cir-19-0121 |
0.388 |
|
| 2019 |
Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, Zhang Z, Lyashchenko SK, Vietri SM, Fung AM, Pentlow KS, Carrasquillo JA, Lewis JS, Larson SM, Cheung NV, et al. Biodistribution and Dosimetry of Intraventricularly Administered I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31405921 DOI: 10.2967/Jnumed.118.219576 |
0.313 |
|
| 2019 |
Casey DL, Lin TY, Cheung NV. Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma. Frontiers in Oncology. 9: 537. PMID 31275859 DOI: 10.3389/Fonc.2019.00537 |
0.362 |
|
| 2019 |
Bailey K, Pandit-Taskar N, Humm JL, Zanzonico P, Gilheeney S, Cheung NV, Kramer K. Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. Journal of Neuro-Oncology. PMID 30879172 DOI: 10.1007/S11060-019-03139-6 |
0.317 |
|
| 2019 |
Casey DL, Kushner BH, Cheung NV, Modak S, Basu EM, Roberts SS, LaQuaglia MP, Wolden SL. Reduced-dose Radiation Therapy to the Primary Site is Effective for High-risk Neuroblastoma: Results from a Prospective Trial. International Journal of Radiation Oncology, Biology, Physics. PMID 30763661 DOI: 10.1016/J.Ijrobp.2019.02.004 |
0.327 |
|
| 2019 |
Kramer K, Pandit-Taskar N, Donzelli M, Wolden SL, Zanzonico P, Humm J, Haque S, Souweidane MM, Lewis J, Lyashchenko SK, Larson SM, Cheung NV. Intraventricular radioimmunotherapy targeting B7H3 for CNS malignancies. Journal of Clinical Oncology. 37: e13592-e13592. DOI: 10.1200/Jco.2019.37.15_Suppl.E13592 |
0.386 |
|
| 2019 |
Yankelevich M, Modak S, Chu R, Lee DW, Thakur A, Cheung NV, Lum LG. Phase I study of OKT3 x hu3F8 bispecific antibody (GD2Bi) armed T cells (GD2BATs) in GD2-positive tumors. Journal of Clinical Oncology. 37: 2533-2533. DOI: 10.1200/Jco.2019.37.15_Suppl.2533 |
0.382 |
|
| 2019 |
Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Zanzonico P, Donzelli M, Lyashchenko SK, Haque S, Thakur SB, Cheung NV, Larson SM, Dunkel IJ. A phase I study of convection-enhanced delivery of 124I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma: An update with dose-response assessment. Journal of Clinical Oncology. 37: 2008-2008. DOI: 10.1200/Jco.2019.37.15_Suppl.2008 |
0.355 |
|
| 2019 |
Mora J, Kushner BH, Flores MA, Santa-María V, Garraus M, Basu EM, Roberts SS, Castañeda A, Gorostegui M, Cheung NV, Modak S. Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study. Journal of Clinical Oncology. 37: 10025-10025. DOI: 10.1200/Jco.2019.37.15_Suppl.10025 |
0.329 |
|
| 2019 |
Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV. High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident primary refractory metastases in bone marrow (BM). Journal of Clinical Oncology. 37: 10024-10024. DOI: 10.1200/Jco.2019.37.15_Suppl.10024 |
0.345 |
|
| 2019 |
Park JA, Guo Hf, Xu H, Cheung NV. PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma Blood. 134: 1959-1959. DOI: 10.1182/Blood-2019-131325 |
0.333 |
|
| 2019 |
Bailey K, Pandit-Taskar N, Humm J, Zanzonico P, Gilheeney S, Cheung N, Kramer K. Ther-24. Targeted Radioimmunotherapy For Embryonal Tumor With Multilayered Rosettes Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz036.229 |
0.321 |
|
| 2018 |
Cheal SM, Xu H, Guo HF, Patel M, Punzalan B, Fung EK, Lee SG, Bell M, Singh M, Jungbluth AA, Zanzonico PB, Piersigilli A, Larson SM, Cheung NV. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. Theranostics. 8: 5106-5125. PMID 30429889 DOI: 10.7150/Thno.26585 |
0.415 |
|
| 2018 |
Modak S, Le Luduec JB, Cheung IY, Goldman DA, Ostrovnaya I, Doubrovina E, Basu E, Kushner BH, Kramer K, Roberts SS, O'Reilly RJ, Cheung NV, Hsu KC. Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. Oncoimmunology. 7: e1461305. PMID 30221057 DOI: 10.1080/2162402X.2018.1461305 |
0.535 |
|
| 2018 |
Wu Z, Guo H, Xu H, Cheung NV. Development of a tetravalent anti-GPA33/anti-CD3 bispecific antibody for colorectal cancers. Molecular Cancer Therapeutics. PMID 30082472 DOI: 10.1158/1535-7163.Mct-18-0026 |
0.361 |
|
| 2018 |
Hoseini SS, Guo H, Wu Z, Hatano MN, Cheung NV. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Advances. 2: 1250-1258. PMID 29858209 DOI: 10.1182/Bloodadvances.2017014373 |
0.365 |
|
| 2018 |
Suzuki M, Kushner BH, Kramer K, Basu EM, Roberts SS, Hammond WJ, LaQuaglia MP, Wolden SL, Cheung NV, Modak S. Treatment and outcome of adult-onset neuroblastoma. International Journal of Cancer. PMID 29574715 DOI: 10.1002/Ijc.31399 |
0.355 |
|
| 2018 |
Casey DL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL. Dose-escalation is needed for gross disease in high-risk neuroblastoma. Pediatric Blood & Cancer. PMID 29469198 DOI: 10.1002/Pbc.27009 |
0.305 |
|
| 2018 |
Ahmed M, Lopez-Albaitero A, Pankov D, Santich BH, Liu H, Yan S, Xiang J, Wang P, Hasan AN, Selvakumar A, O'Reilly RJ, Liu C, Cheung NV. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. Jci Insight. 3. PMID 29467338 DOI: 10.1172/Jci.Insight.97805 |
0.524 |
|
| 2018 |
Wu Z, Santich BH, Liu H, Liu C, Cheung NV. Targeting Intracellular Antigens with pMHC-Binding Antibodies: A Phage Display Approach. Methods in Molecular Biology (Clifton, N.J.). 1701: 255-269. PMID 29116509 DOI: 10.1007/978-1-4939-7447-4_13 |
0.338 |
|
| 2018 |
Park JA, Xu H, Santich B, Cheung NV. Exceptionally Potent Cytotherapy Using T Cells Armed with Novel Tetravalent Recombinant Bispecific Antibodies Specific for GD2 and HER2 Blood. 132: 4536-4536. DOI: 10.1182/Blood-2018-99-120210 |
0.35 |
|
| 2018 |
Spitzer B, Gundem G, Farnoud N, Millard N, McGovern E, Patel M, Levine M, Medina J, Zhou Y, Arango Ossa JE, Walsh MF, Levine RL, Cheung IY, Armstrong SA, Cheung NV, et al. Early Detection and Molecular Characterization of Therapy-Related Leukemia in Children Reveals Patterns of Disease Transformation and Guides Future Surveillance Protocols Blood. 132: 291-291. DOI: 10.1182/Blood-2018-99-120005 |
0.328 |
|
| 2018 |
Park JA, Xu H, Cheung I, Cheung NV. Abstract B38: Tetravalent bispecific antibodies specific for HER2 and disialoganglioside GD2 to engage polyclonal T cells for osteosarcoma therapy Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-B38 |
0.443 |
|
| 2018 |
Suzuki M, Xu H, Guo H, Nemieboka B, Wu Z, Lewis J, Cheung NV. Abstract A30: Novel T-cell engaging antibodies against L1CAM for neuroblastoma Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-A30 |
0.401 |
|
| 2018 |
Modak S, Carrasquillo J, LaQuaglia M, Pat Z, Heaton T, Cheung N, Pandit-Taskar N. Abstract CT006: Intraperitoneal radioimmunotherapy for desmoplastic small round cell tumor: Results of a phase I study (NCT01099644) Clinical Trials. DOI: 10.1158/1538-7445.Am2018-Ct006 |
0.307 |
|
| 2017 |
Kushner BH, LaQuaglia MP, Modak S, Wolden SL, Basu EM, Roberts SS, Kramer K, Yataghene K, Cheung IY, Cheung NV. MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy. Oncotarget. 8: 95293-95302. PMID 29221128 DOI: 10.18632/Oncotarget.20513 |
0.368 |
|
| 2017 |
Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. Oncoimmunology. 6: e1358331. PMID 29147617 DOI: 10.1080/2162402X.2017.1358331 |
0.373 |
|
| 2017 |
Kramer K, Pandit-Taskar N, Humm JL, Zanzonico PB, Haque S, Dunkel IJ, Wolden SL, Donzelli M, Goldman DA, Lewis JS, Lyashchenko SK, Khakoo Y, Carrasquillo JA, Souweidane MM, Greenfield JP, ... ... Cheung NV, et al. A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma. Pediatric Blood & Cancer. PMID 28940863 DOI: 10.1002/Pbc.26754 |
0.324 |
|
| 2017 |
Wu Z, Cheung NV. T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics. Pharmacology & Therapeutics. PMID 28834699 DOI: 10.1016/J.Pharmthera.2017.08.005 |
0.365 |
|
| 2017 |
Hoseini SS, Dobrenkov K, Pankov D, Xu XL, Cheung NV. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2. Oncoimmunology. 6: e1320625. PMID 28680755 DOI: 10.1080/2162402X.2017.1320625 |
0.378 |
|
| 2017 |
Park JA, Cheung NV. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treatment Reviews. 58: 22-33. PMID 28622628 DOI: 10.1016/J.Ctrv.2017.05.006 |
0.309 |
|
| 2017 |
Hoseini SS, Cheung NV. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. Cancer Letters. PMID 28428075 DOI: 10.1016/J.Canlet.2017.04.013 |
0.378 |
|
| 2017 |
Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Mar Ferrandiz M, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NV, Mora J, et al. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 28412222 DOI: 10.1016/J.Jconrel.2017.04.016 |
0.388 |
|
| 2017 |
Lopez-Albaitero A, Xu H, Guo H, Wang L, Wu Z, Tran H, Chandarlapaty S, Scaltriti M, Janjigian Y, de Stanchina E, Cheung NV. Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. Oncoimmunology. 6: e1267891. PMID 28405494 DOI: 10.1080/2162402X.2016.1267891 |
0.403 |
|
| 2017 |
Souweidane MM, Kramer K, Pandit-Taskar N, Zanzonico P, Zhou Z, Donzelli M, Lyashchenko SK, Haque S, Thakur SB, Cheung NV, Larson SM, Dunkel IJ. A phase I study of convection enhanced delivery (CED) of 124I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma (DIPG). Journal of Clinical Oncology. 35: 2010-2010. DOI: 10.1200/Jco.2017.35.15_Suppl.2010 |
0.348 |
|
| 2017 |
Suzuki M, Kushner BH, Kramer K, Basu EM, Roberts SS, LaQuaglia MP, Cheung NV, Modak S. Anti-GD2 immunotherapy in adults with high-risk neuroblastoma (HR-NB): The Memorial Sloan Kettering Cancer Center (MSKCC) experience. Journal of Clinical Oncology. 35: 10550-10550. DOI: 10.1200/Jco.2017.35.15_Suppl.10550 |
0.378 |
|
| 2017 |
Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Tomlinson U, Wolden SL, Zanzonico P, John HL, Haque S, Souweidane MM, Greenfield J, Basu EM, Roberts SS, Carrasquillo JA, Lewis JS, ... ... Cheung NV, et al. A curative approach to central nervous system metastases of neuroblastoma. Journal of Clinical Oncology. 35: 10545-10545. DOI: 10.1200/Jco.2017.35.15_Suppl.10545 |
0.359 |
|
| 2017 |
Kramer K, Kushner B, Modak S, Pandit-Taskar N, Tomlinson U, Donzelli M, Wolden S, Zanzonico P, Humm J, Haque S, Souweidane M, Greenfield J, Basu E, Roberts S, Carrasquillo J, ... ... Cheung N, et al. SCDT-38. SAFETY AND EFFICACY OF INTRAVENTRICULAR 131I-LABELED MONOCLONAL ANTIBODY 8H9 TARGETING THE SURFACE GLYCOPROTEIN B7-H3 IN PATIENTS WITH CNS/LM DISEASE Neuro-Oncology. 19: vi272-vi272. DOI: 10.1093/Neuonc/Nox168.1119 |
0.39 |
|
| 2016 |
Dobrenkov K, Ostrovnaya I, Gu J, Cheung IY, Cheung NV. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatric Blood & Cancer. PMID 27304202 DOI: 10.1002/Pbc.26097 |
0.356 |
|
| 2016 |
Xu H, Guo H, Cheung IY, Cheung NV. Antitumor efficacy of anti-GD2 IgG1 is enhanced by Fc glyco-engineering. Cancer Immunology Research. PMID 27197064 DOI: 10.1158/2326-6066.Cir-15-0221 |
0.371 |
|
| 2016 |
Forlenza CJ, Boudreau JE, Zheng J, Le Luduec JB, Chamberlain E, Heller G, Cheung NV, Hsu KC. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27069083 DOI: 10.1200/Jco.2015.64.9558 |
0.383 |
|
| 2016 |
Suzuki M, Cheung IY, Cheung NV. Idiotype network induced by anti-GD2 immunotherapy is associated with long-term survival in patients with neuroblastoma. Journal of Clinical Oncology. 34: 10570-10570. DOI: 10.1200/Jco.2016.34.15_Suppl.10570 |
0.36 |
|
| 2016 |
Dobrenkov K, Ostrovnaya I, Cheung IY, Feng Y, Cheung NV. GD2/GD3 expression: Companion diagnostic for ganglioside-targeted immunotherapy against pediatric solid tumors. Journal of Clinical Oncology. 34: 10567-10567. DOI: 10.1200/Jco.2016.34.15_Suppl.10567 |
0.394 |
|
| 2016 |
Kushner BH, Modak S, LaQuaglia MP, Wolden SL, Basu EM, Roberts SS, Kramer K, Cheung IY, Cheung NV. Event-free survival (EFS) and overall survival (OS) of MYCN-amplified stage 2/3 neuroblastoma with or without autologous stem-cell transplantation (ASCT). Journal of Clinical Oncology. 34: 10553-10553. DOI: 10.1200/Jco.2016.34.15_Suppl.10553 |
0.304 |
|
| 2016 |
Roberts SS, Ogando Y, Ostrovnaya I, Fattahi F, Cheung I, Cheung NV, Studer L, Tomishima M. Abstract A08: Using directed differentiation of human pluripotent stem cells and gene expression profiling to characterize the cell of origin of neuroblastoma Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-A08 |
0.342 |
|
| 2015 |
Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NV. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. PMID 26623730 DOI: 10.18632/Oncotarget.6393 |
0.395 |
|
| 2015 |
Cheal SM, Xu H, Guo HF, Lee SG, Punzalan B, Chalasani S, Fung EK, Jungbluth A, Zanzonico PB, Carrasquillo JA, O'Donoghue J, Smith-Jones PM, Wittrup KD, Cheung NV, Larson SM. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity (86)Y- or (177)Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. European Journal of Nuclear Medicine and Molecular Imaging. PMID 26596724 DOI: 10.1007/S00259-015-3254-8 |
0.346 |
|
| 2015 |
Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal SM, Guo HF, Larson SM, Cheung NV. Humanized Affinity-Matured Monoclonal Antibody 8H9 Has Potent Anti-Tumor Activity and Binds to FG Loop of B7-H3. The Journal of Biological Chemistry. PMID 26487718 DOI: 10.1074/Jbc.M115.679852 |
0.353 |
|
| 2015 |
Tsao CY, Sabbatino F, Cheung NV, Hsu JC, Villani V, Wang X, Ferrone S. Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells. Oncoimmunology. 4: e1023975. PMID 26405581 DOI: 10.1080/2162402X.2015.1023975 |
0.361 |
|
| 2015 |
Ross RA, Walton JD, Han D, Guo HF, Cheung NV. A distinct gene expression signature characterizes human neuroblastoma cancer stem cells. Stem Cell Research. 15: 419-426. PMID 26342562 DOI: 10.1016/J.Scr.2015.08.008 |
0.314 |
|
| 2015 |
Forlenza CJ, Boudreau JE, Zheng J, Heller G, Cheung NV, Hsu KC. Abstract 2459: KIR3DL1 and HLA-B subtype combinations predict the efficacy of 3F8 monoclonal antibody therapy for neuroblastoma Immunology. 75: 2459-2459. DOI: 10.1158/1538-7445.Am2015-2459 |
0.327 |
|
| 2014 |
Kuo T, Hasan AN, Zhao Q, Selvakumar A, Tassev D, Cheung N, O'Reilly R. T Cells Expressing Cars Directed Against HLA-0201 –Rmf WT-1 Peptide Complex Can Effectively Eradicate WT1+ A0201+ Tumor Cells in-Vitro Biology of Blood and Marrow Transplantation. 20: S132-S133. DOI: 10.1016/J.Bbmt.2013.12.203 |
0.483 |
|
| 2013 |
Modak S, Quaglia MPL, Carrasquillo JA, Zanzonico P, Enero C, Pandit-Taskar N, Kang HJ, Cheung NV. Intraperitoneal radioimmunotherapy (RIT) for desmoplastic small round cell tumor (DSRCT): Initial results from a phase I trial. Journal of Clinical Oncology. 31: 3033-3033. DOI: 10.1200/Jco.2013.31.15_Suppl.3033 |
0.368 |
|
| 2012 |
Rebagay G, Yan S, Liu C, Cheung N. ROR1 and ROR2 in human malignancies: potentials for targeted therapy Frontiers in Oncology. 2: 34-34. PMID 22655270 DOI: 10.3389/Fonc.2012.00034 |
0.352 |
|
| 2012 |
Modak S, Carrasquillo JA, La Quaglia MP, Zanzonico P, Pandit-Taskar N, Lewis JS, Cheung NV. Intraperitoneal radioimmunotherapy (RIT) for desmoplastic small round cell tumor (DSRCT). Journal of Clinical Oncology. 30: TPS9595-TPS9595. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps9595 |
0.391 |
|
| 2010 |
He P, Kramer K, Smith-Jones P, Zanzonico P, Humm J, Larson SM, Cheung NV. Abstract 5633: Two-compartment pharmacokinetics model of radioimmunotherapy with131I-3F8 directly administered into the cerebrospinal fluid Cancer Research. 70: 5633-5633. DOI: 10.1158/1538-7445.Am10-5633 |
0.349 |
|
| 2010 |
Venstrom JM, Zheng J, Kushner BH, Modak S, Danis KE, Cheung IY, Dupont B, Cheung N, Hsu KC. Abstract 5586: NK cell killer Ig-like receptor (KIR) genotype as a novel biomarker for neuroblastoma patients receiving Anti-GD2 monoclonal antibody 3F8 Cancer Research. 70: 5586-5586. DOI: 10.1158/1538-7445.Am10-5586 |
0.363 |
|
| 2009 |
Kushner BH, Kramer K, Modak S, Cheung NV. Reply to K. Satharasinghe et al Journal of Clinical Oncology. 27. DOI: 10.1200/Jco.2009.25.4144 |
0.333 |
|
| 2008 |
Kushner BH, Cheung NV. Neuroblastoma — Linking a Common Allele to a Rare Disease The New England Journal of Medicine. 358: 2635-2637. PMID 18463371 DOI: 10.1056/Nejme0802701 |
0.325 |
|
| 2008 |
Modak S, Pandit‐Taskar N, Kushner BH, Kramer K, Smith‐Jones P, Larson S, Cheung NV. Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy. Pediatric Blood & Cancer. 50: 1271-1273. PMID 17973318 DOI: 10.1002/Pbc.21391 |
0.312 |
|
| 2007 |
Modak S, Cheung NV. Disialoganglioside directed immunotherapy of neuroblastoma Cancer Investigation. 25: 67-77. PMID 17364560 DOI: 10.1080/07357900601130763 |
0.408 |
|
| 2006 |
Kushner BH, Kramer K, Modak S, Cheung NV. Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma Journal of Clinical Oncology. 24: 5271-5276. PMID 17114661 DOI: 10.1200/Jco.2006.06.7272 |
0.329 |
|
| 2006 |
Kushner BH, Budnick A, Kramer K, Modak S, Cheung NV. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 107: 417-422. PMID 16779793 DOI: 10.1002/Cncr.22004 |
0.3 |
|
| 2006 |
Mora J, Lavarino C, Domenech G, Rios J, Gerald W, Torres CD, Cheung N. Identification of candidate tumor related genes using comprehensive gene expression analysis of neuroblastic tumors Journal of Clinical Oncology. 24: 9051-9051. DOI: 10.1200/Jco.2006.24.18_Suppl.9051 |
0.313 |
|
| 2005 |
Alaminos M, Gerald WL, Cheung NV. Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Pediatric Blood & Cancer. 45: 909-915. PMID 16047351 DOI: 10.1002/Pbc.20505 |
0.334 |
|
| 2005 |
Kushner BH, Kramer K, Modak S, Cheung NV. Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma Cancer. 103: 858-862. PMID 15637685 DOI: 10.1002/Cncr.20846 |
0.313 |
|
| 2004 |
Kramer K, Kushner BH, Allen JC, Krol G, Cheung NV. Favorable-biology neuroblastoma presenting with leptomeningeal metastases?: a case presentation. Journal of Pediatric Hematology Oncology. 26: 703-705. PMID 15543002 DOI: 10.1097/00043426-200411000-00003 |
0.374 |
|
| 2004 |
Kushner BH, Kramer K, Modak S, Cheung NV. Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma Clinical Cancer Research. 10: 84-87. PMID 14734455 DOI: 10.1158/1078-0432.Ccr-1147-3 |
0.336 |
|
| 2004 |
Robinson BW, Lee A, Cheung NV, Felix CA. Bone Marrow Replacement with a Clone Harboring Novel t(4;11)(p12;q23) Involving MLL during Neuroblastoma Treatment Is Not Associated with Leukemia. Blood. 104: 2903-2903. DOI: 10.1182/Blood.V104.11.2903.2903 |
0.35 |
|
| 2003 |
Kramer K, Kushner BH, Cheung NV. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. Journal of Pediatric Hematology Oncology. 25: 601-605. PMID 12902911 DOI: 10.1097/00043426-200308000-00003 |
0.33 |
|
| 2003 |
Mora J, Gerald WL, Cheung NV. Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Letters. 197: 119-124. PMID 12880970 DOI: 10.1016/S0304-3835(03)00094-6 |
0.359 |
|
| 2003 |
Gupta M, Steinherz PG, Cheung N, Steinherz L. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Medical and Pediatric Oncology. 40: 343-347. PMID 12692800 DOI: 10.1002/Mpo.10298 |
0.327 |
|
| 2002 |
Cheung NV, Modak S, Vickers A, Knuckles B. Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies Cancer Immunology, Immunotherapy. 51: 557-564. PMID 12384807 DOI: 10.1007/S00262-002-0321-3 |
0.33 |
|
| 2002 |
Kushner BH, Kramer K, Cheung NV. Chronic neuroblastoma: Indolent Stage 4 disease in children Cancer. 95: 1366-1375. PMID 12216106 DOI: 10.1002/Cncr.10800 |
0.341 |
|
| 2001 |
Cheung NV, Kushner BH, Kramer K. Monoclonal antibody-based therapy of neuroblastoma. Hematology-Oncology Clinics of North America. 15: 853-864. PMID 11765377 DOI: 10.1016/S0889-8588(05)70255-0 |
0.399 |
|
| 2001 |
Kushner BH, Kramer K, Cheung NV. Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma Journal of Clinical Oncology. 19: 4189-4194. PMID 11709561 DOI: 10.1200/Jco.2001.19.22.4189 |
0.354 |
|
| 2001 |
Kramer K, Cheung NV. Antibody-based diagnostic and therapeutic innovations for human cancer. Comprehensive Therapy. 27: 183-194. PMID 11569318 DOI: 10.1007/S12019-001-0013-5 |
0.35 |
|
| 2001 |
Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NV. Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma Medical and Pediatric Oncology. 36: 194-196. PMID 11464881 DOI: 10.1002/1096-911X(20010101)36:1<194::Aid-Mpo1046>3.0.Co;2-B |
0.403 |
|
| 2001 |
Mora J, Gerald WL, Qin J, Cheung NV. Molecular Genetics of Neuroblastoma and the Implications for Clinical Management: A Review of the MSKCC Experience Oncologist. 6: 263-268. PMID 11423673 DOI: 10.1634/Theoncologist.6-3-263 |
0.301 |
|
| 2000 |
Mora J, Akram M, Cheung NV, Chen L, Gerald WL. Laser-capture microdissected schwannian and neuroblastic cells in stage 4 neuroblastomas have the same genetic alterations. Medical and Pediatric Oncology. 35: 534-537. PMID 11107110 DOI: 10.1002/1096-911X(20001201)35:6<534::Aid-Mpo7>3.0.Co;2-R |
0.311 |
|
| 2000 |
Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NV. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Medical and Pediatric Oncology. 35: 468-474. PMID 11070479 DOI: 10.1002/1096-911X(20001101)35:5<468::Aid-Mpo5>3.0.Co;2-P |
0.377 |
|
| 1999 |
Kushner BH, Kramer K, Cheung NV. Oral Etoposide for Refractory and Relapsed Neuroblastoma Journal of Clinical Oncology. 17: 3221-3225. PMID 10506622 DOI: 10.1200/Jco.1999.17.10.3221 |
0.312 |
|
| 1999 |
Modak S, Kramer K, Gerald W, Cheung NV. Diganglioside GD2 and Antigen 8H9: Potential Targets for Antibody-Based Immunotherapy against Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma Pediatric Research. 45: 150-150. DOI: 10.1203/00006450-199904020-00890 |
0.392 |
|
| 1998 |
Kushner BH, Cheung NV, Kramer K, Heller G, Jhanwar SC. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. Journal of Clinical Oncology. 16: 3880-3889. PMID 9850034 DOI: 10.1200/Jco.1998.16.12.3880 |
0.333 |
|
| 1996 |
Medary I, Aronson D, Cheung NV, Ghavimi F, Gerald W, Quaglia MPL. Kinetics of primary tumor regression with chemotherapy: Implications for the timing of surgery Annals of Surgical Oncology. 3: 521-525. PMID 8915482 DOI: 10.1007/Bf02306083 |
0.342 |
|
| 1995 |
Arbit E, Cheung NV, Yeh SDJ, Daghighian F, Zhang JJ, Cordon-Cardo C, Pentlow K, Canete A, Finn R, Larson SM. Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors European Journal of Nuclear Medicine and Molecular Imaging. 22: 419-426. PMID 7641750 DOI: 10.1007/Bf00839056 |
0.411 |
|
| 1994 |
Quaglia MPL, Kushner BH, Heller G, Bonilla MA, Lindsley KL, Cheung NV. Stage 4 neuroblastoma diagnosed at more than 1 year of age: Gross total resection and clinical outcome Journal of Pediatric Surgery. 29: 1162-1166. PMID 7965527 DOI: 10.1016/0022-3468(94)90301-8 |
0.363 |
|
| 1992 |
Ye JN, Cheung NV. A novel O‐acetylated ganglioside detected by anti‐GD2 monoclonal antibodies International Journal of Cancer. 50: 197-201. PMID 1730513 DOI: 10.1002/Ijc.2910500207 |
0.35 |
|
| 1992 |
Kushner BH, Cheung NV. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood. 79: 1484-1490. DOI: 10.1182/Blood.V79.6.1484.Bloodjournal7961484 |
0.354 |
|
| 1990 |
Kushner BH, Gulati SC, O′Reilly RJ, Heller G, Cheung NV. Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro. Medical and Pediatric Oncology. 18: 454-458. PMID 2135871 DOI: 10.1002/Mpo.2950180604 |
0.348 |
|
| 1990 |
Munn DH, Garnick MB, Cheung NV. Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates Blood. 75: 2042-2048. DOI: 10.1182/Blood.V75.10.2042.Bloodjournal75102042 |
0.355 |
|
| 1985 |
Cheung NV, Landmeier B, Ellery S, Neely J, Coccia P. 963 COMPLETE TUMOR ABLATION WITH IODINE 131 RADIOLABELED MONOCLONAL ANTIBODY (Mab) AGAINST HUMAN NEUROBLASTOMA (NB) XENOGRAFTED IN NUDE MICE Pediatric Research. 19. DOI: 10.1203/00006450-198504000-00993 |
0.391 |
|
| 1985 |
Cheung NV, Strandjord SE, Coccia PF, Miraldi F. 896 Imaging Neuroblastoma In Patients With Radiolabeled Monoclonal Antibody As A Basis For Targeting Therapy Pediatric Research. 19. DOI: 10.1203/00006450-198504000-00926 |
0.393 |
|
| 1984 |
Cheung NV, Saarinen U, Donovan D, Landmeier B, Coccia PF. Use Of Monoclonal Antibodies Specific For Neuroblastoma (Nb) In The Detection And Complement Mediated Lysis Of Microscopic Disease Pediatric Research. 18. DOI: 10.1203/00006450-198404001-00866 |
0.381 |
|
| 1983 |
Bussel JB, Kimberly RP, Inman RD, Schulman I, Cunningham-Rundles C, Cheung N, Smithwick EM, O'Malley J, Barandun S, Hilgartner MW. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura Blood. 62: 480-486. PMID 6191803 DOI: 10.1182/Blood.V62.2.480.Bloodjournal622480 |
0.31 |
|
| Show low-probability matches. |